Optimal treatment of painful bone metastases with Samarium EDTMP in a haemodialysis patient: Effectiveness and safety of internal radiotherapy

Nephrology Dialysis Transplantation

Volumn 24, Issue 8, 2009, Pages 2598-2600

  Skalli, Saadia ^a   Desruet, Marie Dominique ^a   Bourre, Jean Cyril ^a   Caravel, Jean Pierre ^a   Vuillez, Jean Philippe ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Bone metastases; Haemodialysis patient; Multiple myeloma; Samarium EDTMP

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; LEXIDRONAM SAMARIUM SM 153; OXIDRONATE TECHNETIUM TC 99M; PAMIDRONIC ACID; RADIOISOTOPE;

AGED; ANALGESIA; ANAMNESIS; ARTICLE; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; BREAST CANCER; CASE REPORT; DRUG HALF LIFE; FEMALE; FEMUR; HEMODIALYSIS PATIENT; HUMAN; PAIN ASSESSMENT; PELVIC GIRDLE; PRIORITY JOURNAL; RIB; SCORING SYSTEM; SHOULDER; SPINE METASTASIS; TIBIA; VISUAL ANALOG SCALE;

AGED; ANALGESICS, NON-NARCOTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; RENAL DIALYSIS; SAMARIUM;

EID: 67651119964     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp148     Document Type: Article

References (13)

1. Cochrane Database for Systematic Reviews. 2005
2. Collins C, Eary JF, Donaldson G et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 1993; 34: 1839-1844
3. Serafini AN, Houston SJ, Resche I et al. Palliation of pain associated with metastatic bone cancer using samarium 153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998; 16: 1574-1581
4. Srikanth M, Davies FE, Morgan GJ. An update on drug combinations for treatment of myeloma. Expert Opin Investig Drugs 2008; 17: 1-12
5. 153Sm-Ethylene diamine tetra methylene phosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 1997; 33:1583-1591
6. Quadramet, European scientific assessment report: Scientific discussion, EMEA 2004
7. Anderson P. Samarium for osteoblastic bone metastases and osteosar-coma. Expert Opin Pharmacother 2006; 7: 1475-1486
8. Serafni AN. Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases. Cancer 2000; 88: 2934-2939
9. Enrique O, Zhonyun P, Prma EP et al. Efficacy and toxicity of Sm-153 EDTMP in the palliative treatment of painful bone metastases. World J Nucl Med 2002; 1: 29-34
10. Dolezal J, Vizda J, Cermakova E. Myelotoxicity after systemic ra-dionuclide therapy of painful bone metastases with 153Samarium-EDTMP. Vnitr Lek 2003; 3: 189-193 [Abstract]
11. Coronado M, Redondo A, Coya J et al. Clinical role of Sm-153 EDTMP in the treatment of painful bone metastatic disease. Clin Nucl Med 2006; 31: 605-610
12. Wang RF, Zhang CL, Zhu SL et al. A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer. Med Princ Pract 2003; 12: 97 - 101
13. Abruzzese E, Iuliano F, Trawinska MM et al. Samarium 153SM: its use in multiple myeloma and report of a clinical experience. Expert Opin Investig Drugs 2008; 17: 1379-1387